Elevated plasma complement components in facioscapulohumeral dystrophy. Issue 11 (17th December 2021)

• Record Type: Journal Article
• Authors: Wong, Chao-Jen; Wang, Leo; Holers, V Michael; Frazer-Abel, Ashley; van der Maarel, Silvère M; Tawil, Rabi; Statland, Jeffrey M; Tapscott, Stephen J
• Is Part Of: Human molecular genetics. Volume 31:Issue 11(2022)
• Page Start: 1821
• Page End: 1829
• Publication Date: 2021-12-17
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddab364
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to several therapeutic approaches entering clinical trials and an increased need to develop biomarkers of disease activity and progression. Multiple prior studies have shown early elevation of RNAs encoding components of the complement pathways and relatively widespread activated complement complexes by immunodetection in FSHD muscle. The current study tested plasma from two independent cohorts of FSHD and control subjects and found elevated complement components in both FSHD cohorts. Combining subjects from both cohorts identified complement factors that best distinguished FSHD and controls. Within the FSHD group, a subset of subjects showed elevation in multiple complement components. Together these findings suggest the need for future studies to determine whether measurements of complement activation can be used as a non-invasive measurement of FSHD disease activity, progression and/or response to therapies. In addition, with the ongoing expansion of complement therapeutic approaches, consideration for precision-based targeting of this pathway is appropriate.